Please assess the completion status of the following clinical trial:

Trial Title: FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Stage III unresectable or American Joint Committee on Cancer (AJCC) stage IV cutaneous, mucosal, ocular, or unknown primary melanoma with measurable disease by physical examination or imaging studies.~* Palpable cutaneous or nodal metastases suitable for punch, trucut, or similar biopsy if the patient agrees.~* Normal electrocardiogram (EKG)~* Left ventricular ejection fraction (LVEF) \> 40% by Multi Gated Acquisition Scan (MUGA)~* Corrected QT (QTc) \< 500 msec~* Age greater than or equal to 18~* Negative pregnancy test~* Fertile patients must use effective contraception~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2~* Normal organ and marrow function~* Patients on hydrochorthiazide should be switched to a potassium-sparing diuretic or another antihypertensive~* At least 4 weeks since prior radiotherapy~* Patients with cardiac hypertrophy may be enrolled but should be carefully monitored.~Exclusion Criteria:~* Prior FR901228 (depsipeptide)~* Prior chemotherapy~* Other concurrent chemotherapy~* Active central nervous system (CNS) metastases by brain computed tomography (CT) scan or magnetic resonance imaging (MRI)~* History of coronary atherosclerotic heart disease~* History of myocardial infarction~* History of congestive heart failure~* Non-melanoma malignancy within the past 5 years except carcinoma in situ or squamous cell or basal cell skin cancer~* Pregnant or nursing women~* Conditions that in the opinion of the investigator would interfere with the ability of the patient to complete this protocol~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to Depsipeptide~* Co-medication with an agent that causes QTc prolongation~* Human immunodeficiency virus (HIV) positive patients receiving combination anti-retroviral therapy~* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements~* Concurrent radiotherapy~* Left ventricular hypertrophy (LVH) on their baseline EKG tracing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Depsipeptide (Type: EXPERIMENTAL): Depsipeptide is administered as a 4-hour IV infusion weekly in doses of 13 mg/m\^2 for 3 weeks. Repeat cycle every 28 days until unacceptable toxicity or disease progression.

Based on this trial design, predict the completion outcome and termination type (if applicable).